SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies around the meme coin, emphasizing its resilience and active development team.  With mentions of breaking all-time highs and a recent listing, the community expresses strong bullish sentiment and encourages others to load up.  The coin's connection to the Solana ecosystem is also a key point of discussion.

its a Meme token and beta to Troll The "Lenny face  is a text-based emoticon, ( ͡° ͜ʖ ͡°), used to convey a range of emotions, particularly mischief, sexual innuendo, or a hidden meaning. It's often employed in online discussions to add a playful or suggestive tone to a message, or sometimes even to spam threads, according to Wikipedia. The symbol is visually interpreted as a face with two eyes (small circles), a nose (squiggly line), and a mouth (curved line).

Lenny

LENNY.X is gaining traction as the original meme coin, tapping into nostalgia and internet culture. Community members refer to themselves as a cult, citing conviction and community as driving forces. Discussions highlight its potential for legendary status within the meme coin landscape on the Solana blockchain.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as a culture-focused crypto, with community members highlighting its association with the cannabis culture and positive vibes. Many are drawn to the community, which they see as a movement, emphasizing freedom, unity, and growth within the digital currency space. The discussion also includes the potential connection to real-world cannabis investments and the broader implications of cannabis legalization.

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.

Avalo Therapeutics Inc

Avalo Therapeutics ($AVTX) is trending due to speculation that positive data from a failed $MLTX trial could indirectly benefit $AVTX. The community is also discussing the high option prices and potential short squeeze. Some traders are looking at $AVTX in sympathy with other low-float biotech stocks that have seen recent gains, while others highlight upcoming investor conferences as potential catalysts.

SPDR Gold Trust - SPDR Gold Shares ETF

SPDR Gold Shares ETF

SPDR Gold Shares ETF ($GLD) is trending as gold prices reach record highs, fueled by expectations of Federal Reserve rate cuts and global economic uncertainty. The community is discussing potential pullbacks and whether this rally is sustainable, with some pointing to central bank buying and a weakening dollar as key drivers. Some traders are questioning the sustainability of the rally and anticipate a correction.

EHang Holdings Ltd. engages in the provision of aerial vehicle technology platform company. It also provides unmanned aerial vehicle (UAV) systems and solutions: air mobility (including human transportation and logistics), smart city management, and aerial media solutions. The firm operates through the following geographical segments: P.R.C., West Asia, East Asia, South America, Europe, and Other. The company was founded by Huazhi Hu and Yifang Derrick Xiong in December 2014 and is headquartered in Guangzhou, China.

EHang Holdings Ltd - ADR

EHang Holdings

EHang Holdings is trending due to community excitement surrounding potential commercial flights in Saudi Arabia and anticipation for the VT35 unveiling. Bullish sentiment is fueled by unusual options activity and analyst price targets, though some investors are wary due to a recent settlement regarding inflated pre-orders. The community is actively discussing the company's potential in the urban air mobility sector and its expansion into new markets.

Green Thumb Industries, Inc. engages in the manufacture and distribution of branded cannabis products. Its brands include RYTHM, Dogwalkers, Beboe, Good Green, Doctor Solomon’s, and &Shine. It operates through the Retail and Consumer Packaged Goods segments. The Retail segment focuses on retailing cannabis to patients and consumers. The Consumer Packaged Goods segment refers to the cultivation, production, and sale of cannabis products to retail stores. The company was founded by Benjamin Kovler and Max Cohen on February 18, 2002 and is headquartered in Chicago, IL.

Green Thumb Industries Inc - Ordinary Shares (Sub Voting)

Green Thumb Industries

Green Thumb Industries is trending as investors closely monitor potential cannabis rescheduling, which could significantly benefit U.S. MSOs by removing tax restrictions and leveling the playing field with Canadian companies. Community discussions revolve around the possibility of rescheduling, with some expressing optimism about potential market catalysts and others remaining skeptical about government action. Despite regulatory uncertainties, GTBIF's financial performance and buyback program are seen as positive indicators, with some viewing it as a leader in the cannabis sector.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending as investors weigh its potential in the quantum computing sector against concerns of dilution and high valuation; community discussions involve bullish outlooks fueled by quantum computing's future and skepticism around profitability and recent announcements. The stock's movement is also being influenced by broader market trends and Nvidia's upcoming quantum event, creating debate around its near-term direction and long-term viability.

Trulieve Cannabis Corp. engages in the provision of medical cannabis products and services. It cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. The company was founded by Kim Rivers & Jason Pernell on September 17, 1940 and is headquartered in Quincy, FL.

Trulieve Cannabis Corp - Ordinary Shares (Sub Voting)

Trulieve Cannabis

Trulieve Cannabis is trending amid growing anticipation for potential cannabis rescheduling, fueled by recent comments from a high profile political figure. The community is buzzing about the possibility of the removal of Section 280E restrictions, which would provide substantial tax relief for cannabis companies, and some are also optimistic about the prospects of recreational legalization in Florida in 2026, where Trulieve has a strong presence.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is trending amid concerns of a potential government shutdown and its possible effects on the markets, with community members actively discussing strategies like buying puts or hedging positions. Talk of Trump's economic policies and their potential impact, as well as analysis of technical indicators, are also contributing to the discussion around SPY. Some traders are pointing to overbought conditions while others remain bullish, citing seasonal patterns or potential for a short squeeze.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BMY Reports Positive Data From a Late-Stage Multiple Myeloma Study

Bristol Myers reports positive phase III results for iberdomide in multiple myeloma, advancing its CELMoD pipeline and portfolio expansion.

MRNA Stock Rises as Updated COVID-19 Jab Shows Strong Immune Response

Moderna jumps after its updated formulation of Spikevax shows an over 8-fold increase in neutralizing antibodies against the LP.8.1 COVID-19 variant in phase IV study.

COVID-19 Vaccine Stocks Fall on Reports Linking Shots to Child Deaths

MRNA, BNTX, PFE and NVAX stocks fall as health officials reportedly plan to link COVID-19 vaccines to child deaths ahead of a key CDC meeting.

BMY-BioNTech Partnership: A Potential Catalyst for Long-Term Gains?

Bristol Myers and BioNTech report strong mid-stage lung cancer trial data for pumitamig, showing high response rates and manageable safety.

Bristol Myers Loses 19.2% in Six Months: Buy, Sell or Hold? 

Bristol Myers struggles with falling shares and legacy drug headwinds, but growth drugs and new approvals help steady revenues.

SMMT Stock Plummets 25% on Regional Data Differences in NSCLC Study

Summit Therapeutics plunges 25% after its HARMONi study shows sharp regional differences in lung cancer trial outcomes.

Pfizer Inc. (PFE) and BioNTech SE (BNTX) announced on Monday that their updated COVID-19 vaccine elicited a robust immune response in a late-stage trial among adults aged 65 and older, as well as those aged 18 through 64 with at least one underlying risk condition.The trial was aimed at evaluating the safety, tolerability, and immunogenicity of a 30-µg dose of the updated vaccine. Preliminary data showed a robust increase in neutralizing antibodies targeting the LP.8.1 sublineage of the COVID-19-causing virus following vaccination, the companies <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-topline-data-demonstrating">said</a>.It added that after 14 days of vaccination, LP.8.1-neutralizing antibody titers exceeded pre-vaccination levels, on average, by at least 4-fold in both age groups. The study enrolled 100 participants.While <a href="https://stocktwits.com/symbol/PFE">PFE stock</a> traded 2% lower at the time of writing, <a href="https://stocktwits.com/symbol/BNTX">BNTX stock</a> fell 7%. On Stocktwits, retail sentiment around PFE stock stayed within ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.<figure class="image"><img style="aspect-ratio:573/59;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_08_at_9_33_39_AM_png_3e721fcb96.webp" alt="PFE's Sentiment Meter and Message Volume as of 9:33 a.m. ET on Sept. 8, 2025 | Source: Stocktwits" width="573" height="59"><figcaption>PFE's Sentiment Meter and Message Volume as of 9:33 a.m. ET on Sept. 8, 2025 | Source: Stocktwits</figcaption></figure>Meanwhile, sentiment around BNTX stayed at ‘extremely bullish’ levels, while retail chatter remained ‘high’.<figure class="image"><img style="aspect-ratio:576/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_08_at_9_34_58_AM_png_9bf1a11796.webp" alt="BNTX's Sentiment Meter and Message Volume as of 9:35 a.m. ET on Sept. 8, 2025 | Source: Stocktwits" width="576" height="62"><figcaption>BNTX's Sentiment Meter and Message Volume as of 9:35 a.m. ET on Sept. 8, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed surprise at PFE stock trading lower after the news.<stembedurl>https://stocktwits.com/Wallst45/message/627799089</stembedurl>The companies stated that the data is intended to reinforce previous findings from vaccine studies and is not meant to replace the post-marketing commitments requested by the U.S. Food and Drug Administration. The safety profile of the vaccine was consistent with previous studies in the trial, with no new safety concerns identified, they added.The updated vaccine received FDA approval last month. To date, five billion doses of the Pfizer-BioNTech COVID-19 vaccine have been distributed globally.While PFE stock is down about 8% this year, BNTX stock is down over 8%.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/rapport-stock-soars-pre-market-to-head-toward-all-time-highs/chwWU5HRdrd">Rapport Therapeutics Stock Rockets 204% Pre-Market To Head Toward All-Time Highs – Here’s What Happened</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Ruth Jones, Immunization Nurse, holds a Pfizer-BioNTech COVID-19 vaccine (brand name: Comirnaty) at Borinquen Health Care Center on May 29, 2025 in Miami, Florida

Pfizer, BioNTech’s Updated COVID-19 Vaccine Shows Robust Immune Response In Late-Stage Study – More Details Inside

The companies stated that the data is intended to reinforce previous findings from vaccine studies and is not meant to replace the post-marketing commitments requested by the U.S. Food and Drug Administration. 

Equity

The companies stated that the data is intended to reinforce previous findings from vaccine studies and is not meant to replace the post-marketing commitments requested by the U.S. Food and Drug Administration. 


BioNTech SE (BNTX) announced on Friday that a late-stage trial, conducted by its partner Duality Biologics in China, has met its primary endpoint of progression-free survival at a pre-specified interim analysis. The trial is evaluating Trastuzumab Pamirtecan versus Trastuzumab Emtansine in patients with certain types of breast cancer.Shares of the company traded 10% higher in the pre-market session on Friday. The <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.biontech.de/news-releases/news-release-details/biontech-and-dualitybio-announce-phase-3-trial-adc-candidate">trial</a> enrolled 228 patients with HER2-positive unresectable or metastatic breast cancer, an aggressive form of the disease that has spread and cannot be surgically removed, who previously received Trastuzumab and a taxane-based chemotherapy.On Stocktwits, retail sentiment around BNTX stock jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:577/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_05_at_8_57_36_AM_png_5a9988a80e.webp" alt="BNTX's Sentiment Meter and Message Volume as of 8:57 a.m. ET on Sept. 5, 2025 | Source: Stocktwits" width="577" height="60"><figcaption>BNTX's Sentiment Meter and Message Volume as of 8:57 a.m. ET on Sept. 5, 2025 | Source: Stocktwits</figcaption></figure> DualityBio now plans to discuss the next steps with the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China regarding the submission of an application for Trastuzumab Pamirtecan approval.DualityBio Global Medical Officer Hua Mu noted that breast cancer has a high incidence rate in China, with over 350,000 new cases annually.“Together with our partner BioNTech, we plan the development of Trastuzumab Pamirtecan in further tumor types towards BLA application in other regions including the United States and the European Union to maximize its potential for patients around the world,” Mu said.BioNTech also noted that this is the first positive late-stage data readout achieved in the collaboration between the two companies initiated in April 2023. The collaboration aims to accelerate the development of differentiated antibody drug-conjugate therapeutics for solid tumors.BioNTech holds global commercial rights for Trastuzumab Pamirtecan, while DualityBio has commercial rights for Mainland China, Hong Kong Special Administrative Region, and Macau Special Administrative Region.BNTX stock is down by 9% this year but up by about 15% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-proposes-whopping-1-trillion-pay-package-for-ceo-elon-musk/chwIJkaRdpr">Tesla Proposes Whopping $1 Trillion Pay Package For CEO Elon Musk</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the BioNTech logo is displayed on a smartphone screen. (Photo illustration by Cheng Xin/Getty Images)

Why Did BioNTech Stock Surge 10% Pre-Market Today?

DualityBio now plans to discuss the next steps with the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China regarding the submission of an application for Trastuzumab Pamirtecan approval.

Pfizer Inc. (PFE) and BioNTech SE (BNTX) said on Wednesday that the U.S. Food and Drug Administration has approved the application of its LP.8.1-adapted monovalent COVID-19 vaccine for use in senior adults as well as in younger individuals who are at risk of severe outcomes from the infection.The agency approved the vaccine for use in adults aged 65 years and older, as well as in individuals aged 5 through 64 years with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.The companies <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontechs-comirnatyr-receives-us-fda-approval">said</a> that the approval is based on a body of evidence supporting the safety and efficacy of the vaccine, including clinical trial data supporting approval for children 5 through 11 years of age.On Stocktwits, retail sentiment around PFE trended within ‘neutral’ territory over the past 24 hours while message volume stayed at ‘low’ levels.<figure class="image"><img style="aspect-ratio:622/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_27_at_2_09_36_PM_png_c697ca4665.webp" alt="PFE's Sentiment Meter and Message Volume as of 2:10 p.m. ET on Aug. 27, 2025 | Source: Stocktwits" width="622" height="60"><figcaption>PFE's Sentiment Meter and Message Volume as of 2:10 p.m. ET on Aug. 27, 2025 | Source: Stocktwits</figcaption></figure>Meanwhile, sentiment around BNTX stayed within ‘bullish’ territory, accompanied by ‘high’ levels of retail chatter.<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2025_08_27_at_2_10_26_PM_png_722e599af9.webp" alt="Screenshot 2025-08-27 at 2.10.26 PM.png"><figcaption>BNTX's Sentiment Meter and Message Volume as of 2:10 p.m. ET on Aug. 27, 2025 | Source: Stocktwits</figcaption></figure>The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance, the companies said. The companies added that the vaccine will begin shipping immediately and be available in pharmacies, hospitals, and clinics across the U.S. in the coming days.Earlier in the day, U.S. Health Secretary Robert F. Kennedy Jr. <a href="https://stocktwits.com/news-articles/markets/equity/robert-kennedy-jr-announces-end-of-fda-covid-mandates/chsUJ4VRdla">stated</a> in a post on X that the FDA has now granted full marketing authorization for certain COVID-19 vaccines targeting higher-risk groups. Moderna’s (MRNA) shot has been authorized for individuals six months and older, Pfizer's (PFE) for ages five and up, and Novavax's (NVAX) for ages 12 and above, all of whom are at higher risk, he said.“The American people demanded science, safety, and common sense,” Kennedy said.Moderna <a target="_blank" rel="noopener noreferrer nofollow" href="https://feeds.issuerdirect.com/news-release.html?newsid=6729249760870595&amp;symbol=MRNA">confirmed</a> the news and said that the FDA has approved its 2025-2026 formulas for Spikevax and mNEXSPIKE, targeting the LP.8.1 variant of SARS-CoV-2 to help prevent COVID-19. The updated vaccines are expected to be available in the coming days, it said.While Spikevax is now approved in adults over 65 and in people aged 6 months through 64 years at high risk, mNEXSPIKE is approved for individuals 12 through 64 years of age at high risk and all adults over 65, the company said.While PFE stock is down by 6% this year, BNTX stock is down by 9%.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/uk-regulator-approves-biogen-drug-for-treating-postnatal-depression/chsUel3Rdl9">UK Regulator Approves Biogen’s Drug For Treating Postnatal Depression</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Optimism has also been recently driven by Pfizer’s solid quarterly performance.

Pfizer, BioNTech Get FDA Clearance For Updated Covid Vaccine In Senior Adults And Younger At-Risk Population

The agency approved the vaccine for use in adults aged 65 years and older, as well as in individuals aged 5 through 64 years with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.

BMY Stock Trades Near 52-Week Low: Time to Buy or Sell? 

BMY trims earnings outlook despite revenue beat and upbeat drug sales, sending shares to a 52-week low before a rebound. We recommend investors to stay on the sidelines for now. 

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

Current Price	$98.08
Prev Close	$98.08
Open	$98.50
Dividend Yield	0.00%
50-Day Moving Average	$106.30
Beta	0.77
Avg. Volume	762,996.05
PE Ratio	-61.93

52-Week High	$129.27
52-Week Low	$81.20
Market Capitalization	$23.58B
EPS (Annual)	-$2.99
Price to Book	1.09
Revenue Per Employee	$439,432.88
Enterprise Value/EBITDA	N/A

BNTX
BioNTech SE - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BNTX News

BNTX BioNTech SE - ADR